Enzolytics Inc (ENZC)

[falon]

ALL RISE

Here comes ENZC!!!

ENZOLYTICS REPORTS PROGRESS ON ITS MULTIPLE THERAPEUTICS PLATFORMS AND INITIATIVES


News Release April 19, 2021


We continue to make great strides in applying our multiple platforms for the production of therapeutics for treating infectious diseases. Our future success will follow as we meet our goals to bring these therapeutics to market with new developments made possible by our extensive platform for producing new and effective therapies.

We acknowledge our partners Genscript (https://www.genscript.com), STC Biologics (https://stcbiologics.com), and California National Primate Research Center (University of Southern California) for their continued support in our research and development efforts. We are also grateful for the overwhelming support from world-renowned scientists and continue to expand our team of advisors to build a strong company based on research and development.

We are encouraged by the positive feedback received from pharmaceutical companies who have acknowledged an interest in partnering upon the achievement of defined milestones. The milestones we have set include the following:

Monoclonal Antibodies for Treatment of HIV Milestones


3rd Milestone: Animal Studies of anti-HIV Monoclonal Antibodies at California National Primate Research Center, University of Southern California

Time to completion: 6 months following in vitro testing in process.

5th Milestone: Production of additional Monoclonal Antibodies targeting identified sites (epitopes) on the HIV

Status: in process. Time to completion: 5-6 months

COVID-19

SARS-CoV-2 (Coronavirus) Monoclonal Antibodies Milestones

2nd Milestone: Production of Monoclonal Antibodies targeting identified sites (epitopes) on the SARS-CoV-2 virus

Status: In process. Time to completion: 3-4 months

3rd Milestone: Fast-Track Clinical Studies

Time to Completion: 6 months following the production of Monoclonal Antibodies

Production of Monoclonal Antibodies for HTLV-1/2


We are committed to developing universal, durable, and broadly neutralizing Monoclonal Antibodies for many infectious diseases. We have entered into an "intent to partner" agreement with a pharmaceutical company to create Monoclonal Antibodies against HTLV-1/2. We expect to complete the production by the end of 2021.

Monoclonal Antibodies for HTLV-1/2 Milestones


2nd Milestone: Creation of anti-HTLV1/2 Monoclonal Antibodies

Time to completion: 6-8 months following identification of target epitopes

CEO Charles Cotropia said, “The strength of our Company lies in our multiple technology platforms and the ability to produce fully human Monoclonal Antibodies against conserved and immutable targets on identified viruses. The viruses that may be addressed using our technology range from HIV to the Coronavirus to HTLV-1/2 to Ebola and many more. These numerous targeted viruses and bacteria are listed on our website [https://enzolytics.com/proprietary-therapeutics/]. We will continue to provide updates on our developments and progress toward completing the milestones we have set. We thank all our shareholders for their ongoing support of our Company and its technologies.”
https://www.otcmarkets.com/stock/ENZC/news/Enzolytics-Reports-Progress-On-Its-Multiple-Therapeutics-Platforms-and-Initiatives?id=298785


With most milestones completed or near completion it is time for ENZC to take the next step in the process and thus today we found out who will be providing their services to move ENZC forward.

· Enzolytics Inc. to leverage Samsung Biologics’ development and manufacturing expertise to advance both Anti-HIV and Anti-SARS-CoV-2 Monoclonal Antibody Therapies to IND.

· Samsung Biologics to offer a seamless, end-to-end CDMO service with support from its San Francisco R&D Center.



Development of therapeutic antibodies for the treatment of diseases
https://jbiomedsci.biomedcentral.com/articles/10.1186/s12929-019-0592-z

Production Processes for Monoclonal Antibodies
https://www.intechopen.com/books/fermentation-processes/production-processes-for-monoclonal-antibodies

Final Thought:

Regardless of the exact path that gives rise to the next generation of monoclonal antibody therapies, one thing is for certain: therapeutic antibodies can do things that few small molecules can, and as such will remain firmly a part of the drug development landscape for years to come.
https://www.nuventra.com/resources/blog/monoclonal-antibodies-past-present-and-future/